Stockreport

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF Successful completion of end-of-Phase 2 interactions with FDA on the development of denifanstat for MASH; Phase 3 program initiation expected by end of 2024 Anticipat [Read more]